The novel vasopressin receptor (V1aR) antagonist SRX246 reduces anxiety in an experimental model in humans: a randomized proof-of-concept study-Reference-Cited by-同舟云学术

The novel vasopressin receptor (V1aR) antagonist SRX246 reduces anxiety in an experimental model in humans: a randomized proof-of-concept study

Published:2021-05-10 Issue:9 Volume:238 Page:2393-2403
ISSN:0033-3158
Container-title:Psychopharmacology
language:en
Short-container-title:Psychopharmacology

Author:

Lago Tiffany R.,Brownstein Michael J.,Page Emily,Beydler Emily,Manbeck Adrienne,Beale Alexis,Roberts Camille,Balderston Nicholas,Damiano Eve,Pineles Suzanne L.,Simon Neal,Ernst Monique,Grillon Christian

Funder

National Institutes of Health

Azevan Pharmaceuticals Inc

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s00213-021-05861-4.pdf

Reference74 articles.

1. Åkerlund M, Bossmar T, Brouard R et al (1999) Receptor binding of oxytocin and vasopressin antagonists and inhibitory effects on isolated myometrium from preterm and term pregnant women. Br J Ostet Gynaecol 106:1047–1053

2. Anderzhanova E, Kirmeier T, Wotjak CT (2017) Animal models in psychiatric research: the RDoC system as a new framework for endophenotype-oriented translational neuroscience. Neurobiol Stress 7:47–56

3. Avery SN, Clauss JA, Blackford JU (2016) The human BNST: functional role in anxiety and addiction. Neuropsychopharmacology 41:126–141

4. Baas JMP, Grillon C, Böcker KBE et al (2002) Benzodiazepines have no effect on fear-potentiated startle in humans. Psychopharmacology 161:233–247

5. Ballard ED, Ionescu DF, Vande VJL et al (2014) Increased fear-potentiated startle in major depressive disorder patients with lifetime history of suicide attempt. J Affect Disord 162:34–38

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ANXIOLYTICS: Origins, drug discovery, and mechanisms;Pharmacology Biochemistry and Behavior;2024-12

2. Discovery and evaluation of a novel 18F-labeled vasopressin 1a receptor PET ligand with peripheral binding specificity;Acta Pharmaceutica Sinica B;2024-09

3. Neurolipidomic insights into anxiety disorders: Uncovering lipid dynamics for potential therapeutic advances;Neuroscience & Biobehavioral Reviews;2024-08

4. Validity of mental and physical stress models;Neuroscience & Biobehavioral Reviews;2024-03

5. Effects of arginine vasopressin on human anxiety and associations with sex, dose, and V1a-receptor genotype;Psychopharmacology;2024-02-15